New injection for rheumatoid arthritis enters first human safety tests

NCT ID NCT05576012

Completed Disease control Sponsor: Lipum AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new biologic drug called SOL-116 in 56 healthy volunteers and people with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug, not whether it works. Participants received a single injection of SOL-116 or a placebo, and researchers monitored for side effects. This is the first step in seeing if SOL-116 could become a future treatment for rheumatoid arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SOL-116 (a biologic drug given as an injection)
What this could lead to: If safe and effective in later trials, SOL-116 could become a new treatment option to help control rheumatoid arthritis symptoms.
What could go wrong: This is a very early Phase 1 study focused on safety, not on whether the drug works. It involves only 56 people, so results may not apply to everyone, and the drug may fail in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

CHDR (Stichting Centre for Human Drug Research)

Leiden, Netherlands
QPS Netherlands B.V.

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.